EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Risk of post‐injection endophthalmitis peaks within the first three injections of anti‐vascular endothelial growth factor therapy: A nationwide registry‐based study

Benjamin Sommer Thinggaard iD, Frederik Pedersen iD, Ryo Kawasaki, Jimmi Wied, Yousif Subhi iD, Jakob Grauslund iD, Lonny Stokholm

Acta Ophthalmologica · 2024-12 · 102 (8) · 953-962

DOI: 10.1111/aos.16727 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Acta Ophthalmologica, online erschienen am 03.06.2024. Verfasst von Benjamin Sommer Thinggaard und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Odense University Hospital, Odense, Denmark. Hauptthemen laut MEDLINE: Endophthalmitis, Intravitreal Injections, Registries, Angiogenesis Inhibitors. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

To report the incidence of post‐injection endophthalmitis (PIE) and the cumulative risk associated with repeated injections of intravitreal anti‐vascular endothelial growth factor (anti‐VEGF).

Methods

We employed nationwide registries in Denmark to include all individuals aged ≥40 years who received at least one intravitreal anti‐VEGF injection in 2007–2022. Our primary endpoint PIE was identified using specific diagnostic codes for endophthalmitis and procedure codes for vitreous biopsy within 10 days prior to and 120 days post‐injection. Patients were stratified according to the underlying diagnoses for which they received the treatment. The relative risk (RR) for PIE was calculated between groups based on the number of injections received by the patients.

Results

We identified 60 825 patients who received intravitreal anti‐VEGF treatment during study time, with a median age of 77.2 years and females constituting 58.1%. We identified 232 cases of PIE after 1 051 549 injections during follow‐up, resulting in an incidence of 0.022% [95% CI 0.019%–0.025%]. Despite a linear growth in annual anti‐VEGF use, the incidence remained stable at 0.020% [95% CI 0.017%–0.023%] from 2013 to 2022. Compared to patients receiving 1–3 injections, RR for patients receiving 4–20, 21–40, and >40 injections were 0.46 [95% CI 0.34–0.63], 0.32 [95% CI 0.21–0.50], and 0.54 [95% CI 0.36–0.81], respectively. Findings were similar across the different diagnoses.

Conclusions

Based on 16 years of nationwide registry data, this study identified a low and stable incidence of PIE. Notably, the highest risk of endophthalmitis was within the first three anti‐VEGF injections.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

EndophthalmitisIntravitreal InjectionsRegistriesAngiogenesis InhibitorsVascular Endothelial Growth Factor AHumansFemaleMaleAgedIncidenceDenmarkRisk FactorsMiddle AgedRanibizumabRetrospective StudiesFollow-Up StudiesAdultAged, 80 and overRisk AssessmentBevacizumab

Stichwörter der Autor:innen

anti‐VEGFdiabetic macular edemaneovascular age‐related macular degenerationpost‐injection endophthalmitisretinal vein occlusion

Substanzen

Angiogenesis InhibitorsVascular Endothelial Growth Factor ARanibizumabBevacizumab

Autor:innen und Institutionen

  • Department of Ophthalmology, Odense University Hospital, Odense, Denmark.
  • Department of Clinical Research, University of Southern Denmark, Odense, Denmark.
  • OPEN, Open Patient Data Explorative Network, Odense University Hospital, Odense, Denmark.
  • Division of Public Health, Department of Social Medicine, Graduate School of Medicine, Osaka University, Osaka, Japan.
  • Department of Ophthalmology, Rigshospitalet, Glostrup, Denmark.
  • Department of Ophthalmology, Zealand University Hospital, Roskilde, Denmark.

ORCID-Profile: Benjamin Sommer Thinggaard, Frederik Pedersen, Yousif Subhi, Jakob Grauslund

Zitieren

APA

Thinggaard, B. S., Pedersen, F., Kawasaki, R., Wied, J., Subhi, Y., Grauslund, J., & Stokholm, L. (2024). Risk of post‐injection endophthalmitis peaks within the first three injections of anti‐vascular endothelial growth factor therapy: A nationwide registry‐based study. Acta Ophthalmologica, 102(8), 953-962. https://doi.org/10.1111/aos.16727

Vancouver

Thinggaard BS, Pedersen F, Kawasaki R, Wied J, Subhi Y, Grauslund J, et al. Risk of post‐injection endophthalmitis peaks within the first three injections of anti‐vascular endothelial growth factor therapy: A nationwide registry‐based study. Acta Ophthalmologica. 2024;102(8):953-962. doi:10.1111/aos.16727

BibTeX
@article{Thinggaard2024,
  author = {Thinggaard, Benjamin Sommer and Pedersen, Frederik and Kawasaki, Ryo and Wied, Jimmi and Subhi, Yousif and Grauslund, Jakob and Stokholm, Lonny},
  title = {Risk of post‐injection endophthalmitis peaks within the first three injections of anti‐vascular endothelial growth factor therapy: A nationwide registry‐based study},
  journal = {Acta Ophthalmologica},
  year = {2024},
  volume = {102},
  number = {8},
  pages = {953--962},
  doi = {10.1111/aos.16727}
}
Kostenlos starten →